首页 > R&D Systems > R&D Systems/Human TrkA Antibody/AF175-SP/25 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Human TrkA Antibody/AF175-SP/25 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

AF175-SP-25ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

SpeciesReactivityHumanSpecificityDetectshumanTrkAindirectELISAsandWesternblots. IndirectELISAs,approximately50%cross-reactivitywithrecombinantratTrkAisobserved and10%cross-reactivitywithrecombinanthuman(rh) TrkBandrhTrKCisobserved.SourcePolyclonalGoatIgGPurificationAntigenAffinity-purifiedImmunogenMousemyelomacelllineNS0-derivedrecombinanthumanTrkAAla33-Glu407Accession#AAA36770FormulationLyophilizedfroma0.2μmfilteredsolutioninPBSwithTrehalose.*Smallpacksize(SP)issuppliedasa0.2µmfilteredsolutioninPBS.EndotoxinLevelLabelUnconjugatedWesternBlot1µg/mLSeebelowFlowCytometry2.5µg/106cellsK562humanchronicmyelogenousleukemiacelllineImmunohistochemistry5-15µg/mLSeebelowCyTOF-readyReadytobelabeledusingestablishedconjugationmethods.NoBSAorothercarrierproteinsthatcouldinterferewithconjugation.NeutralizationMeasuredbyitsABIlitytoneutralizebeta‑NGF-inducedproliferationintheTF‑1humanerythroleukemiccellline.Kitamura,T.etal.(1989)J.CellPhysiol.140:323.TheNeutralizationDose(ND50)istypically3-12 µg/mLinthepresenceof5 ng/mLRecombinantHumanbeta‑NGF.ReconstitutionReconstituteat0.2mg/mLinsterilePBS.ShippingTheproductisshippedatambienttemperature.Uponreceipt,storeitimmediatelyatthetemperaturerecommendedbelow.*Smallpacksize(SP)isshippedwithpolarpacks.Uponreceipt,storeitimmediatelyat-20to-70°CStability&StorageUseamanualdefrostfreezerandavoidrepeatedfreeze-thawcycles.12monthsfromdateofreceipt,-20to-70°Cassupplied.1month,2to8°Cundersterileconditionsafterreconstitution.6months,-20to-70°Cundersterileconditionsafterreconstitution.References:Esposito,D.etal.(2001)J.Biol.Chem.276:32687.Sofroniew,M.V.etal.(200)Annu.Rev.Neurosci.24:1217.LongName:NeurotrophicTyrosineKinaseReceptorAEntrezGeneIDs:4914(Human);59109(Rat)AlternateNames:DKFZp781I14186;EC2.7.10;EC2.7.10.1;MTChighaffinitynervegrowthfactorreceptor;Neurotrophictyrosinekinasereceptortype1;neurotrophictyrosinekinase,receptor,type1;NTRK1;NTRK-1;p140-TrkA;TRK1-transformingtyrosinekinaseprotein;TrkA;Trk-A;TRKAOncogeneTRK;TRKTRK1;tyrosinekinasereceptorABackground:TrkA,theproductoftheproto-oncogenetrk,isamemberoftheneurotrophictyrosinekinasereceptorfamilythathasthreemembers.TrkA,TrkBandTrkCpreferentiallybindNGF,NT-4andBDNF,andNT-3,respectively.AllTrkfamilyproteinsshareaconservedcomplexsubdomainorganizationconsistingofasignalpeptide,twocysteine-richdomains,aclusterofthreeleucine-richmotifs,andtwoimmunoglobulin-likedomainsintheextracellularregion,aswellasanintracellularregionthatcontainsthetyrosinekinasedomain.TwodistinctTrkAisoformsthatdifferbyvirtueofa6-aminoacidinsertionintheirextracellulardomainhavebeenidentified.ThelongerTrkAisoformistheonlyisoformexpressedwithinneuronaltissueswhereastheshorterTrkAisexpressedmainlyinnon-neuronaltissues.NGFbindstoTrkAwithlowaffinityandactivatesitscytoplasmickinase,initiatingasignalingcascadethatmediatesneuronalsurvivalanddifferentiation.HigheraffinitybindingofNGFrequiresthecoexpressionofTrkAwiththep75NGFreceptor(NGFR),amemberofthetumornecrosisfactorreceptorsuperfamily.NGFRbindsallneurotrophinswithlowaffinityandmodulatesTrkactivityaswellasaltersthespecificityofTrkreceptorsfortheirligands.NGFRcanalsomediatecelldeathwhenexpressedindependentofTrk.

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。